Bio-Path Holdings Appoints Amy P. Sing, M.D. to its Board of Directors
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the appointment of Amy P. Sing, M.D. to its Board of Directors, bringing the number of board members to five.
Dr. Sing, 56, currently serves as Senior Director of Medical Affairs at Genomic Health, Inc., a leading publicly held biotechnology company that assists physicians and patients in making personalized cancer treatment decisions. From 2004 to 2011, Dr. Sing worked in various leadership and research positions at Genentech, Inc. Most notably, Dr. Sing led the oversight of the Investigator Sponsored Trials (IST) program for the now approved breast cancer drug Avastin. Dr. Sing’s experience in the biotechnology sector also includes directing research teams for Seattle Genetics, Inc. and Program Leader for CellPro, Incorporated. Dr. Sing started her career in drug development at Fred Hutchinson Cancer Research Center and the University of Washington. Throughout her career, Dr. Sing has received numerous awards for her work, including from the National Cancer Institute, American Cancer Society and Stanford University. Dr. Sing holds a B.A. from Amherst College and an M.D. from Stanford University.
“I believe Amy will make an excellent addition to our Board of Directors, and I am pleased to welcome her to the team,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path. “Amy’s experience in bringing cancer treatments to market will be of tremendous benefit as Bio-Path continues to move its product pipeline through the clinic.”
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company’s website at http://www.biopathholdings.com.
Sorry. No data so far.